Found: 16
Select item for more details and to access through your institution.
Pharmacokinetics, pharmacodynamics, tolerability and prediction of clinically effective dose of ACT‐774312: A novel CRTH2 antagonist.
- Published in:
- Basic & Clinical Pharmacology & Toxicology, 2019, v. 124, n. 6, p. 711, doi. 10.1111/bcpt.13197
- By:
- Publication type:
- Article
In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022, v. 8, n. 1, p. 1, doi. 10.1002/trc2.12306
- By:
- Publication type:
- Article
Modeling the Effect of the Selective S1P Receptor Modulator Ponesimod on Subsets of Blood Lymphocytes.
- Published in:
- Pharmaceutical Research, 2017, v. 34, n. 3, p. 599, doi. 10.1007/s11095-016-2087-x
- By:
- Publication type:
- Article
Estimation of Attainment of Steady‐State Conditions for Compounds With a Long Half‐Life.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, n. 1, p. 82, doi. 10.1002/jcph.1701
- By:
- Publication type:
- Article
Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.
- Published in:
- British Journal of Clinical Pharmacology, 2017, v. 83, n. 3, p. 476, doi. 10.1111/bcp.13149
- By:
- Publication type:
- Article
Modelling pharmacokinetics and pharmacodynamics of the selective S1P<sub>1</sub> receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients.
- Published in:
- British Journal of Clinical Pharmacology, 2020, v. 86, n. 4, p. 791, doi. 10.1111/bcp.14182
- By:
- Publication type:
- Article
Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P<sub>1</sub> Receptor Modulator Ponesimod Based on 13 Clinical Studies.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P<sub>1</sub> Receptor Modulator Ponesimod.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 6, p. 1083, doi. 10.1002/cpt.877
- By:
- Publication type:
- Article
Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 1, p. 74, doi. 10.1002/psp4.12877
- By:
- Publication type:
- Article
Systemic exposures of gantenerumab: An integrated population pharmacokinetics (popPK) analysis across multiple clinical studies.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.083055
- By:
- Publication type:
- Article
GRADUATE I and II: Subgroup analysis and correlations of biomarkers.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.082995
- By:
- Publication type:
- Article
Re‐estimation of drug‐specific amyloid removal parameters and the rate constant for pathogenic tau turnover brings the Q‐ATN model into better alignment with recent phase 3 data from gantenerumab and lecanemab.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.076222
- By:
- Publication type:
- Article
Re‐estimation of drug‐specific amyloid removal parameters and the rate constant for pathogenic tau turnover brings the Q‐ATN model into better alignment with recent phase 3 data from gantenerumab and lecanemab.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.076222
- By:
- Publication type:
- Article
Open RoAD: Design and baseline characteristics of an open‐label rollover study evaluating long‐term safety and tolerability of subcutaneous gantenerumab in participants with early Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.063261
- By:
- Publication type:
- Article
Development of a quantitative semi‐mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q‐ATN model).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 6, p. 2287, doi. 10.1002/alz.12877
- By:
- Publication type:
- Article
Linking amyloid to clinical outcome: A quantitative semi‐mechanistic model based on the A/T/N biomarker framework to simulate the natural history of Alzheimer's disease and the effects of anti‐amyloid treatment.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 3, p. 1, doi. 10.1002/alz.067069
- By:
- Publication type:
- Article